Category Archives: Public Policy

Latest From Public Policy

Sen Menendez Asks SEC to Investigate IPR Abuses

Securities and Exchange Commission

New Jersey Senator Bob Menendez has asked the Securities and Exchange Commissioner (SEC) to investigate a new investment scheme designed to manipulate the stock prices of companies engaged in research and development of innovative medical therapies, to determine if the practice is illegal. As reported in this Bloomberg Business article, certain investment firms are shorting the stocks of patent-dependent life sciences companies and then using new patent litigation procedures to challenge their patents and drive Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Time: How to Breathe New Life Into America’s Health-Care System

21st Century Cures Act

Last week, Rep. Fred Upton (R-MI) published an op-ed – How to Breathe New Life Into America’s Health-Care System – in Time Magazine on the potential of the 21st Century Cures Act to ‘help modernize the health-care innovation infrastructure, incorporate a patient perspective into the drug and device approval process, support advances in personalized medicine, streamline clinical trials, and provide more resources to support cutting-edge research and help young scientists.’ Rep. Upton points out that there are Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

11 Days Until BIO 2015: IP Networking and Meetup Opportunities

BIO Convention Networking

This year’s BIO International Convention is fast approaching, with plenty of opportunities for the best and brightest in the biotech IP sector to meet and discuss the most pressing issues affecting the industry today. Here are some of the receptions, networking, and meet-up opportunities for the Intellectual Property Track at this year’s convention: Monday: Kickoff Concert (Open to Convention Access registrants and higher) 6:30 p.m.-9:30 p.m. Liacouras Center Philadelphia is home to a rich musical Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Morning Consult: Right-Sized Regulations, Innovation and Investor Protection

Jim Greenwood

Today, an op-ed from BIO President and CEO Jim Greenwood appeared in Morning Consult stressing the importance of investor protection by reforming eXtensible Business Reporting Language (XBRL), which is a one-size-fits-all costly reporting requirement that can harm company growth and investor returns. Congressman Robert Hurt (R-VA) introduced a bill – the Small Company Disclosure Simplification Act (H.R. 1965) – that would provide a temporary exemption from XBRL for newly public and low-revenue companies in order Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

Tick Size Pilot Program: A Few Pennies Make a Big Difference


Earlier this week, the Securities and Exchange Commission (SEC) approved a tick size pilot program that will begin next year. We issued this statement, praising the SEC for finalizing this program, which could improve liquidity and enhance capital formation for emerging biotech companies. Under current SEC rules, all securities on the public market are priced in $0.01 increments known as “tick sizes.” The switch to the standard tick size of a penny was enacted in 2000 Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,